{"filing":{"accession_number":"0001437749-26-028590","cik":"0001668243","ticker":"URGN","company_name":"UroGen Pharma Ltd.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-18","primary_document":"urgn20260819_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm"},"events":[{"id":28690,"run_id":26252,"accession_number":"0001437749-26-028590","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"UroGen entered into an Option and Research License Agreement with IntraGel Therapeutics on August 18, 2026, obtaining exclusive options to license IntraGel's SRGel platform for head and neck cancer treatment and other indications, coupled with a $7 million equity investment commitment. This is a material strategic partnership and licensing arrangement that expands the company's product pipeline and development capabilities, but does not constitute a traditional M\u0026A transaction (no acquisition or change of control), debt issuance, or other specifically-named event type. It is clearly operational/strategic in nature and material to investors assessing the company's growth prospects.","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30721,"accession_number":"0001437749-26-028590","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"UroGen entered into an Option and Research License Agreement with IntraGel Therapeutics on August 18, 2026, obtaining exclusive options to license IntraGel's SRGel platform for head and neck cancer treatment and other indications, coupled with a $7 million equity investment commitment. This is a material strategic partnership and licensing arrangement that expands the company's product pipeline and development capabilities, but does not constitute a traditional M\u0026A transaction (no acquisition or change of control), debt issuance, or other specifically-named event type. It is clearly operational/strategic in nature and material to investors assessing the company's growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:06:39.181728+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30721,"accession_number":"0001437749-26-028590","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"UroGen entered into an Option and Research License Agreement with IntraGel Therapeutics on August 18, 2026, obtaining exclusive options to license IntraGel's SRGel platform for head and neck cancer treatment and other indications, coupled with a $7 million equity investment commitment. This is a material strategic partnership and licensing arrangement that expands the company's product pipeline and development capabilities, but does not constitute a traditional M\u0026A transaction (no acquisition or change of control), debt issuance, or other specifically-named event type. It is clearly operational/strategic in nature and material to investors assessing the company's growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:06:39.181728+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-08-20"}]}